UK hits pharma companies with £266 million fines for overcharging health service
The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10